Glycemic control: The SUSTAIN-1 trial demonstrated that semaglutide improved glycemic control, with a mean HbA1c reduction of 2.3% from baseline
GLP-3 R Price range: $99.99 through $249.99 Reta (Triple Agonist) Product Overview Reta is a synthetic unimolecular peptide and a potent triple agonist targeting the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG) receptors
prepartum luteolysis: regulatory mechanisms governing canine corpus luteum function
Mechanisms of Weight Loss (The Brain and Gut) GLP-1 RAs promote weight loss through a gut-brain axis, acting on receptors in the CNS and gastrointestinal tract to regulate energy balance (Zheng et al., 2024)
Whether you're optimizing a liposomal formulation for proof-of-concept studies or preparing for scale-up, BOC Sciences provides the scientific partnership and operational agility you need to move forward with confidence
It is not a sleep aid, drug or treatment, has no regulatory approval, and is not intended for human or veterinary use
